Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.
暂无分享,去创建一个
L. Hemphill | Alison M. Rope | S. Grinspoon | M. Torriani | H. Makimura | Meghan N. Feldpausch | Hang Lee
[1] T. McLaughlin,et al. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. , 2011, The Journal of clinical endocrinology and metabolism.
[2] J. Després,et al. Effect of rimonabant on carotid intima–media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial , 2011, Heart.
[3] S. Grinspoon,et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. , 2011, The Journal of clinical endocrinology and metabolism.
[4] L. Hemphill,et al. Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity. , 2009, The Journal of clinical endocrinology and metabolism.
[5] N. Møller,et al. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. , 2009, Endocrine reviews.
[6] K. Ho,et al. Faculty Opinions recommendation of Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. , 2009 .
[7] M. C. Savanelli,et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. , 2009, The Journal of clinical endocrinology and metabolism.
[8] S. M. You,et al. The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. , 2008, The Journal of clinical endocrinology and metabolism.
[9] L. Hemphill,et al. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. , 2008, The Journal of clinical endocrinology and metabolism.
[10] S. Heymsfield,et al. Femoral-gluteal subcutaneous and intermuscular adipose tissues have independent and opposing relationships with CVD risk. , 2008, Journal of applied physiology.
[11] D. Potvin,et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. , 2007, The New England journal of medicine.
[12] G. Mancini,et al. Visceral Adipose Tissue, a Potential Risk Factor for Carotid Atherosclerosis: Results of the Multicultural Community Health Assessment Trial (M-CHAT) , 2007, Stroke.
[13] A. Munafo,et al. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. , 2005, European journal of endocrinology.
[14] S. Grottoli,et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. , 2005, European journal of endocrinology.
[15] A. Rissanen,et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.
[16] J. Elashoff,et al. Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. , 2004, The Journal of clinical endocrinology and metabolism.
[17] Andrew R. Coggan,et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. , 2004, The New England journal of medicine.
[18] R. Ross,et al. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. , 2003, American journal of physiology. Endocrinology and metabolism.
[19] M. Espeland,et al. Associations of Extracranial Carotid Atherosclerosis Progression With Coronary Status and Risk Factors in Patients With and Without Coronary Artery Disease , 2002, Circulation.
[20] D. Cook,et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. , 2002, The Journal of clinical endocrinology and metabolism.
[21] F. Lönnqvist,et al. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding , 2002, International Journal of Obesity.
[22] M. Schambelan,et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. , 2002, The Journal of clinical endocrinology and metabolism.
[23] H. Pijl,et al. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. , 2001, The Journal of clinical endocrinology and metabolism.
[24] E. Arvat,et al. Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults , 2001, Endocrine.
[25] J. Després,et al. Elevated C-Reactive Protein: Another Component of the Atherothrombotic Profile of Abdominal Obesity , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[26] Raymond Chan,et al. Anisotropic edge-preserving smoothing in carotid B-mode ultrasound for improved segmentation and intima-media thickness (IMT) measurement , 2000, Computers in Cardiology 2000. Vol.27 (Cat. 00CH37163).
[27] P. Wahl,et al. Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. , 1999, Diabetes care.
[28] B. Bengtsson,et al. Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults , 1999, The Lancet.
[29] H. Orskov,et al. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. , 1997, The American journal of physiology.
[30] J D Veldhuis,et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. , 1991, The Journal of clinical endocrinology and metabolism.
[31] A Tremblay,et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. , 1990, Arteriosclerosis.
[32] D L Kaiser,et al. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion. , 1985, The Journal of clinical investigation.
[33] W. Vale,et al. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour , 1982, Nature.
[34] N. Ling,et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. , 1982, Science.
[35] K. Kovacs,et al. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. , 1982, The Journal of clinical investigation.
[36] G. Borkan,et al. Assessment of abdominal fat content by computed tomography. , 1982, The American journal of clinical nutrition.
[37] V. Dávila-Román,et al. Effect of Moderate Diet-Induced Weight Loss and Weight Regain on Cardiovascular Structure and Function , 2010 .
[38] N. Tritos,et al. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. , 2009, The Journal of clinical endocrinology and metabolism.
[39] B. Cha,et al. Visceral fat amount is associated with carotid atherosclerosis even in type 2 diabetic men with a normal waist circumference , 2009, International Journal of Obesity.
[40] Moyses Szklo,et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. , 2002, American journal of epidemiology.